Moving toward response-adapted trials in oncology

Nat Med. 2024 Dec;30(12):3426-3428. doi: 10.1038/s41591-024-03346-3.

Jose Pérez-García^{1

2}, Gabriele Antonarelli^{3

4}, Maria Gion^{5

6}, Antonio Llombart-Cussac^{1

7

8}, Javier Cortés^{9

10

11

12}

¹ Scientific Department, Medica Scientia Innovation Research (MEDSIR)-Oncoclínicas & Co., Jersey City, NJ, USA.
² International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
³ Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
⁴ Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy.
⁵ IOB-Madrid, Beata María Ana Hospital, Madrid, Spain.
⁶ Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain.
⁷ Universidad Católica de Valencia, Valencia, Spain.
⁸ Hospital Arnau de Vilanova, Valencia, Spain.
⁹ Scientific Department, Medica Scientia Innovation Research (MEDSIR)-Oncoclínicas & Co., Jersey City, NJ, USA. [email protected].
¹⁰ International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain. [email protected].
¹¹ IOB Madrid, Hospital Beata María Ana, Madrid, Spain. [email protected].
¹² Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain. [email protected].

No abstract available